While the 2023 annual San Antonio Breast Cancer Symposium (SABCS) did not bring practice-changing data for to the treatment of triple negative breast cancer (TNBC), the general sessions did feature three interesting studies in this breast cancer subtype. First, a 5-year update of KEYNOTE-522 further solidified the clinical benefit of perioperative pembrolizumab in patients with early-stage TNBC.1 In contrast, the phase III Alexandra/IMpassion030 study failed to show a clinical benefit from the addition of atezolizumab to adjuvant chemotherapy in this setting.2 In the advanced setting, the phase II KEYLYNK trial yielded promising results with a combination of pembrolizumab and olaparib following induction therapy with pembrolizumab and chemotherapy in patients with BRCA-mutant, locally advanced, or metastatic TNBC.3
